To support its R&D activities on Chagas disease, DNDi launched the Chagas Clinical Research Platform (CCRP). The platform brings together partners, experts, and stakeholders to provide support for evaluation and development of new treatments for Chagas disease. The patient-centred platform aims to f...acilitate clinical research, provide a forum for technical discussions, develop a critical mass of expertise, and strengthen institutional research capacities. In addition, it identifies and reviews priority needs, works towards standardization of methodology to assess drug efficacy and reviews alternatives for using current approved drugs (new schemes, doses, combination) and special scenarios (resistance).
more
PLoS Negl Trop Dis 15(8): e0009697. Chagas disease (CD), caused by the parasite Trypanosoma cruzi, affects ~6–7 million people worldwide. Significant limitations still exist in our understanding of CD. Harnessing individual participant data (IPD) from studies could support more in-depth analyses t...o address the many outstanding research questions. This systematic review aims to describe the characteristics and treatment practices of clinical studies in CD and assess the breadth and availability of research data for the potential establishment of a data-sharing platform.
more
Die Initiative Medikamente gegen vernachlässigte Krankheiten (Drugs for Neglected Diseases initiative, DNDi) ist eine internationale gemeinnützige Organisation, die sichere, wirksame und bezahlbar...e Behandlungen für die am meisten vernachlässigten Patient:innen erforscht, entwickelt und bereitstellt.
more
La Iniciativa Medicamentos para Enfermedades Olvidadas (DNDi) es una organización internacional sin fines de lucro que proporciona tratamientos seguros, eficaces y asequibles para los pacientes más desatendidos, desde el laboratorio hasta su llegada a las manos de las poblaciones más vulnerables ...del mundo.
more
L’initiative Médicaments contre les Maladies Négligées (DNDi) est une organisation internationale à but non lucratif spécialisée dans la recherche, le développement et la mise à disposition de traitements sûrs, efficaces et abordables aux patients les plus négligés.
A Iniciativa Medicamentos para Doenças Negligenciadas (DNDi) é uma organização internacional sem fins lucrativos que disponibiliza medicamentos seguros, eficazes e acessíveis para doenças negligenciadas, desde o laboratório até sua chegada às mãos das populações mais vulneráveis do mund...o.
more
August 26, 2021
https://doi.org/10.1371/journal.pntd.0009678
In January 2021, the World Health Organization (WHO) published a new road map to address the burden of disease and death imposed by neglected tropical diseases (NTDs). The end of the first year of t...he 2021-2030 NTD road map is an opportunity to take stock of where we stand and how we plan to move forward.
Considerable progress has been made since 2012 when the first road map was adopted. As of 6 June 2022, forty-six countries have eliminated at least one NTD, while 600 million people no longer require treatment because they are no longer exposed to risks associated with the pathogens that previously harmed them. In some cases, diseases that have plagued humanity for centuries, such as sleeping sickness and Guinea worm disease, are at an all-time low. Less tangible, but also important, there has been significant progress in the way NTDs are viewed. Additionally, the disruptive impact of the COVID-19 pandemic on NTD programmes is evident.
This brochure is the first in a series of advocacy briefs for the new NTD road map presenting highlights of success and challenges towards attaining the 2030 goals.
more
Building on the progress of the London Declaration on Neglected Tropical Diseases (NTDs) and putting individuals and communities at the centre of the NTD response, we, the signatories of this declar...ation, come together to commit to ending NTDs.
Available in different languages
more
Despite a historical association with poor tolerability, a comprehensive review on safety of antileishmanial chemotherapies is lacking. We carried out an update of a previous systematic review of all published clinical trials in visceral leishmaniasis (VL) from 1980 to 2019 to document any reported ...serious adverse events (SAEs).
more
Leptospirosis, a spirochaetal zoonosis, occurs in diverse epidemiological settings and affects vulnerable populations, such as rural subsistence farmers and urban slum dwellers. Although leptospirosis is a life-threatening disease and recognized as an important cause of pulmonary haemorrhage syndrom...e, the lack of global estimates for morbidity and mortality has contributed to its neglected disease status
more
Diabetes Poster - Does your child show any of these symptoms?
The leishmaniases are a group of diseases caused by Leishmania spp., which occur in cutaneous, mucocutaneous and visceral forms. They are neglected tropical ...x">diseases (NTDs), which disproportionately affect marginalized populations who have limited access to health care. HIV co-infected patients with Leishmania infection are highly infectious to sandflies, and an increase in the coinfection rate in an endemic area is likely to increase the effective infective reservoir.
more
Analysis of microfilaria prevalence data from 430 communities
A systematic review of clinical and observational antiparasitic treatment studies to assess the potential for establishing an individual participant-level data platform.
Chagas disease (CD), caused by the parasite Trypanosoma cruzi, affects ~6–7 million people worldwide. Significant limitations s...till exist in our understanding of CD. Harnessing individual participant data (IPD) from studies could support more in-depth analyses to address the many outstanding research questions. This systematic review aims to describe the characteristics and treatment practices of clinical studies in CD and assess the breadth and availability of research data for the potential establishment of a data-sharing platform.
more
Chagas Disease (CD) affects 6–7 million people worldwide and isrelated topoverty-promo ting conditions. Chronic asymptomatic cases are mostly invisible tohealth systems. Aiming totranslate CD discoveries into education/information practices toraise alertness and empowerment ofaffected people; and ...toperform an active search of CD cases, articulating intersectoral actions toimprove the access ofinfected people tothe local health service for the treatment of CD; our research group developed and tested under field conditions as innovative social technology: an itinerant education interdisciplinarysetting named “Chagas Express XXI”
more
In 2005, the World Health Organization (WHO) recognized Chagas disease (CD; Trypanosoma cruzi infection) as a neglected tropical disease (NTD) [1] and included it into the global plan to combat NTDs [2]. The Target 3.3 of the United Nations Sustaina...ble Development Goals (UN/SDG) aims at ending the epidemics of NTDs by 2030 [3]. Mother-to-child (congenital/connatal) transmission is currently the main mode of transmission of T. cruzi over blood transfusions and organ transplantations in vector-free areas within and outside Latin America (LA). Based on recent demonstrations that congenital transmission can be prevented [4–7], WHO has shifted its objective, in 2018, from control to elimination of congenital CD (cCD).
more
Chagas disease (CD), caused by the parasite Trypanosoma cruzi, affects ~6–7 million people worldwide. Significant limitations still exist in our understanding of CD. Harnessing individual participant data (IPD) from studies could support more in-depth analyses to address
the many outstanding rese...arch questions. This systematic review aims to describe the characteristics and treatment practices of clinical studies in CD and assess the breadth and
availability of research data for the potential establishment of a data-sharing platform.
more
A wide spectrum of disease severity has been described for Human African Trypanosomiasis (HAT) due to
Trypanosoma brucei rhodesiense (T.b. rhodesiense), ranging from chronic disease patterns in southern countries of East Africa to an increase in virulence towards the north. However, only limited d...ata on the clinical presentation of T.b. rhodesiense HAT is available. From 2006-2009 we conducted the first clinical trial program (I MPAMEL III) in T.b. rhodesiense endemic areas of
Tanzania and Uganda in accordance with international standards (ICH-GCP). The primary and secondary outcome measures were safety and efficacy of an abridged melarsoprol schedule for treatment of second stage disease. Based on diagnostic findings and clinical examinations at baseline we describe the clinical presentation of T.b. rhodesiense HAT in second stage patients from two distinct geographical settings in East Africa.
more